Exelixis Pill Slows Prostate Cancer and Ovarian Tumors in Study - Bloomberg

Exelixis Inc. (EXEL)’s experimental pill
reduced malignant growths in the bones of 86 percent of men with
prostate cancer and cut the spread of tumor cells in one-fourth
of women with ovarian cancer in a company study.

The research sought to gauge the effect of the drug called
XL184 on nine cancer types. Based on the findings released
today, Exelixis plans to conduct larger studies in ovarian and
prostate cancer, said Michael Morrissey, the South San
Francisco-based company’s chief executive officer.